Company achieved significant clinical milestones including Phase 1b enrollment completion and FDA Fast Track designation for CDI-988, indicating regulatory progress and validation of the drug candidate. Receipt of NIH grant funding demonstrates external validation. However, positive sentiment is tempered by declining cash position ($4.7M vs $7.7M) and continued operating losses, which present near-term funding concerns.
Also mentions COCP
Articles that tag COCP but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
